An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels

International Clinical Psychopharmacology

Volumn 20, Issue 3, 2005, Pages 163-168

  Ng, Chee H ^a   Chong, Siow Ann ^b   Lambert, Tim ^a   Fan, Agnes ^a   Hackett, L Peter ^c   Mahendran, Rathi ^b   Subramaniam, Mythily ^b   Schweitzer, Isaac ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b INSTITUTE OF MENTAL HEALTH   (Singapore)

^c Western Australian Centre for Pathology and Medical Research   (Australia)

Author keywords

Clinical efficacy; Clozapine; Inter ethnic comparison; Plasma concentrations; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYTOCHROME P450 1A2; DRUG METABOLITE;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; ASIAN; CAUCASIAN; CIGARETTE SMOKING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; ETHNIC GROUP; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MENTAL DISEASE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RACE DIFFERENCE; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHRONIC DISEASE; CLOZAPINE; DIET; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SINGAPORE; TREATMENT OUTCOME;

EID: 17644384469     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200505000-00007     Document Type: Article

References (32)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
2. Bertilsson L, Carrillo JA, Dahl MI, Llerena A, Alm C, Bondesson U, et al. (1994). Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 38:471-473.
3. Bozikas VP, Papakosta M, Niopas I, Karavatos A, Mirtsou-Fidani V (2004). Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. Eur Neuropsychopharmacol 14:39-44.
4. Breier A, Buchanan RW, Irish D, Carpenter WT (1993). Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Commun Psychiatry 44:1145-1149.
5. Carrillo JA, Herraiz AG, Ramos SI, Benitez J (1998). Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol 18:311-316.
6. Chang WH, Lin SK, Lane HY, Hu WH, Jann MW, Lin HN (1997). Clozapine dosages and plasma drug concentrations. J Formos Med Assoc 96:599-605.
7. Chong SA, Tan CH, Khoo YM, Lee HS, Wong KE, Ngui F, Winslow M (1997). Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. Ther Drug Monit 19:219-223.
8. Day JC, Wood G, Dewey M, Bentall RP (1995). A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 166:650-653.
9. Hogan TP, Awad AG, Eastwood R (1983). A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychiatr Med 13:177-183.
10. Jann MW, Grimsley SR, Gray EC, Chang WH (1993). Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 24:161-176.
11. Kane JM (2004). Remission in Schizophrenia: Global Expert Working Group. Presented at the American Psychiatric Association Annual Meeting, 2004. New York: American Psychiatric Association.
12. Kay S, Fizbein A, Opler L (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
13. Lambert T (1998). Training and Inter-rater reliability using the PANSS; the Australian PANSS Reliability Extension Programme. Schizophr Res 29: 36.
14. Lambert T, Cock N, Alcock SJ, Kelly DL, Conley RR (2003). Measurement of antipsychotic-induced side effects: support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Hum Psychopharmacol Clin Exp 18:405-411.
15. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. (2004). Practice guideline for the treatment of patients with schizophrenia, 2nd edn. Am J Psychiatry 161 (Suppl 1): 1-56.
16. Lindenmayer JP, Bernstein-Hyman R, Grochowski S (1994). A new five factor model of schizophrenia. Psychiatr Quart 65:299-322.
17. Lingjaerde O, Ahlfors UG, Bech P, Denker SJ, Elgen K (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross sectional study of side effects in neuroleptic treated patients. Acta Psychiatr Scand Suppl 334:1-100.
18. Linnet K, Olesen OV (1997). Metabolism of clozapine by cDNA expressed human cytochrome p450 enzymes. Drug Metabol Dispos 25:1379-1382.
19. Liu HC, Chang WH, Wei FC, Lin SK, Lin SK, Jann MW (1996). Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit 18:200-207.
20. Matsuda KT, Cho MC, Lin KM, Smith MW, Young AS, Adams JA (1996). Clozapine dosage, serum levels, efficacy and side effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bull 32:253-257.
21. National Institute of Mental Health (1975). Abnormal Involuntary Movement Scale (AIMS). Early Clin Drug Eval Unit Intercommun 4:3-6.
22. Özdemir V, Kalow W, Posner P, Collins EJ, Kennedy JL, Tang BK, et al. (2001). CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentrations in patients with schizophrenia. J Clin Psychopharmacol 21:398-407.
23. Perry PP, Miller DD, Arndt SV, Cadoret RM (1991). Clozapine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. Am J Psychiatry 148:231-235.
24. Pi EH, Gray GE (1998). A cross-cultural perspective on psychopharmacology. Essent Psychopharmacol 2:233-262.
25. Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, et al. (1994). Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatr 55 (suppl B):133-136.
26. Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ (2004). Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 24:70-78.
27. Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, et al. (2003). Polymorphisms in the cytochrome P450 CYP1A2 gene in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 55:68-76.
28. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
29. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 45:11-12.
30. Todesco L, Torok M, Krahenbuhl S, Wenk M (2003). Determination of - 3858GA and - 164CA genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the - 3858GA mutation between Caucasians and Asians. Eur J Clin Pharmacol 59:343-346.
31. Van der Weide J, Steijns LS, van Weelden MJ (2003). The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 13:169-172.
32. Young CD, Meltzer HY, Deutch AY (1998). Effects of desmethylclozapine on Fos protein expression in the forebrain: in vivo biological activity of the clozapine metabolite. Neuropsychopharmacol 19:99-103.